Experimental CAR-T therapy targets tough T-Cell cancers in new trial

NCT ID NCT07188610

Recruiting now Disease control Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This Phase 2 trial tests a single infusion of PA3-17, a CAR-T cell therapy that targets CD7 on cancer cells, in 100 adults with relapsed or refractory T-lymphoblastic leukemia or lymphoma. Participants receive the treatment after a short chemotherapy prep, and researchers will monitor how well it works and any side effects for up to 24 months. The main goal is to see how many patients achieve a complete or partial response within three months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PA3-17 injection (a type of CAR-T cell therapy that targets CD7 on cancer cells)
What this could lead to: If successful, this could offer a new treatment option for people with hard-to-treat T-cell leukemia or lymphoma who have run out of standard therapies.
What could go wrong: This is a Phase 2 trial with only 100 participants, so results are still early. CAR-T therapies can cause serious side effects like cytokine release syndrome or nervous system problems, and the cancer may still return.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CD7-POSITIVE RELAPSED/REFRACTORY T LYMPHOBLASTIC LEUKEMIA/LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

refractory precursor T-lymphoblastic lymphoma/leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CD7-POSITIVE RELAPSED/REFRACTORY T LYMPHOBLASTIC LEUKEMIA/LYMPHOMA

Contacts and locations

Locations

Facility Name: Guangdong Provincial People's Hospital
NOT_YET_RECRUITING

Guangzhou, Guangdong, 510080, China
Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, 450000, China
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITING

Tianjin, Tianjin Municipality, 300000, China
Jiangsu Province Hospital
RECRUITING

Nanjing, Jiangsu, 210000, China
Peking University People's Hospital
RECRUITING

Beijing, Beijing Municipality, 100000, China
Peking University Third Hospital
RECRUITING

Beijing, Beijing Municipality, 100000, China
Sun Yat-sen University Cancer Center (SYSUCC)
RECRUITING

Guangzhou, Guangdong, 510000, China
The Affiliated Hospital of Xuzhou Medical University
RECRUITING

Xuzhou, Jiangsu, 221000, China
The First Affiliated Hospital of Soochow University
RECRUITING

Suzhou, Jiangsu, 215000, China
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
RECRUITING

Hefei, Anhui, 230000, China
The First Affiliated Hospital of Zhengzhou University
RECRUITING

Zhengzhou, Henan, 450052, China
The First Affiliated Hospital, Zhejiang University School of Medicine
NOT_YET_RECRUITING

Hangzhou, Zhejiang, 310000, China
The First Hospital of Harbin
NOT_YET_RECRUITING

Harbin, Heilongjiang, 150000, China
Tongji Hospital, Tongji University
RECRUITING

Shanghai, Shanghai Municipality, 200000, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430000, China
West China Hospital, Sichuan University (WCHSU)
RECRUITING

Chengdu, Sichuan, 610000, China